Literature DB >> 32868111

Transatlantic registries of pancreatic surgery in the United States of America, Germany, the Netherlands, and Sweden: Comparing design, variables, patients, treatment strategies, and outcomes.

Tara M Mackay1, Elizabeth M Gleeson2, Ulrich F Wellner3, Caroline Williamsson4, Olivier R Busch1, Bas Groot Koerkamp5, Tobias Keck3, Hjalmar C van Santvoort6, Bobby Tingstedt4, Henry A Pitt7, Marc G Besselink8.   

Abstract

BACKGROUND: Registries of pancreatic surgery have become increasingly popular as they facilitate both quality improvement and clinical research. We aimed to compare registries for design, variables collected, patient characteristics, treatment strategies, clinical outcomes, and pathology.
METHODS: Registered variables and outcomes of pancreatoduodenectomy (2014-2017) in 4 nationwide or multicenter pancreatic surgery registries from the United States of America (American College of Surgeons National Surgical Quality Improvement Program), Germany (Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie - Studien-, Dokumentations- und Qualitätszentrum), the Netherlands (Dutch Pancreatic Cancer Audit), and Sweden (Swedish National Pancreatic and Periampullary Cancer Registry) were compared. A core registry set of 55 parameters was identified and evaluated using relative and absolute largest differences between extremes (smallest versus largest).
RESULTS: Overall, 22,983 pancreatoduodenectomies were included (15,224, 3,558, 2,795, and 1,406 in the United States of America, Germany, the Netherlands, and Sweden). Design of the registries varied because 20 out of 55 (36.4%) core parameters were not available in 1 or more registries. Preoperative chemotherapy in patients with pancreatic ductal adenocarcinoma was administered in 27.6%, 4.9%, 7.0%, and 3.4% (relative largest difference 8.1, absolute largest difference 24.2%, P < .001). Minimally invasive surgery was performed in 7.8%, 4.5%, 13.5%, and unknown (relative largest difference 3.0, absolute largest difference 9.0%, P < .001). Median length of stay was 8.0, 16.0, 12.0, and 11.0 days (relative largest difference 2.0, absolute largest difference 8.0, P < .001). Reoperation was performed in 5.7%, 17.1%, 8.7%, and 11.2% (relative largest difference 3.0, absolute largest difference 11.4%, P < .001). In-hospital mortality was 1.3%, 4.7%, 3.6%, and 2.7% (relative largest difference 3.6, absolute largest difference 3.4%, P < .001).
CONCLUSION: Considerable differences exist in the design, variables, patients, treatment strategies, and outcomes in 4 Western registries of pancreatic surgery. The absolute largest differences of 24.3% for the use of preoperative chemotherapy, 9.0% for minimally invasive surgery, 11.4% for reoperation rate, and 3.4% for in-hospital mortality require further study and improvement. This analysis provides 55 core parameters for pancreatic surgery registries.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32868111     DOI: 10.1016/j.surg.2020.07.012

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  5 in total

1.  Comparison of short-term outcomes from the International Oesophago-Gastric Anastomosis Audit (OGAA), the Esophagectomy Complications Consensus Group (ECCG), and the Dutch Upper Gastrointestinal Cancer Audit (DUCA).

Authors: 
Journal:  BJS Open       Date:  2021-05-07

2.  Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies.

Authors:  Nicolò Pecorelli; Alice W Licinio; Giovanni Guarneri; Francesca Aleotti; Stefano Crippa; Michele Reni; Massimo Falconi; Gianpaolo Balzano
Journal:  Front Oncol       Date:  2022-01-10       Impact factor: 6.244

3.  Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer-A Cross-Validation of the National Cancer Database (NCDB) and the German Cancer Registry Group of the Society of German Tumor Centers (GCRG/ADT).

Authors:  Louisa Bolm; Sergii Zemskov; Maria Zeller; Taisuke Baba; Jorge Roldan; Jon M Harrison; Natalie Petruch; Hiroki Sato; Ekaterina Petrova; Hryhoriy Lapshyn; Ruediger Braun; Kim C Honselmann; Richard Hummel; Oleksii Dronov; Alexander V Kirichenko; Monika Klinkhammer-Schalke; Kees Kleihues-van Tol; Sylke R Zeissig; Dirk Rades; Tobias Keck; Carlos Fernandez-Del Castillo; Ulrich F Wellner; Rodney E Wegner
Journal:  Cancers (Basel)       Date:  2022-02-09       Impact factor: 6.639

4.  Feasibility of robotic-assisted pancreatic resection in patients with previous minor abdominal surgeries: a single-center experience of the first three years.

Authors:  Paul Viktor Ritschl; Hannah Kristin Miller; Karl Hillebrandt; Lea Timmermann; Matthäus Felsenstein; Christian Benzing; Brigitta Globke; Robert Öllinger; Wenzel Schöning; Moritz Schmelzle; Johann Pratschke; Thomas Malinka
Journal:  BMC Surg       Date:  2022-03-04       Impact factor: 2.102

5.  Pylorus resection versus pylorus preservation in pancreatoduodenectomy (PyloResPres): study protocol and statistical analysis plan for a German multicentre, single-blind, surgical, registry-based randomised controlled trial.

Authors:  Bernhard W Renz; Christine Adrion; Carsten Klinger; Matthias Ilmer; Jan G D'Haese; Heinz-J Buhr; Ulrich Mansmann; Jens Werner
Journal:  BMJ Open       Date:  2021-11-29       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.